NasdaqGS - Nasdaq Real Time Price • USD
Arvinas, Inc. (ARVN)
At close: June 7 at 4:00 PM EDT
After hours: June 7 at 6:04 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 17 | 19 | 17 | 19 |
| Avg. Estimate | -0.86 | -1.07 | -4.34 | -4.58 |
| Low Estimate | -1.64 | -1.77 | -6.86 | -6.7 |
| High Estimate | 1.16 | 0.8 | -1.69 | -1.24 |
| Year Ago EPS | -1.25 | -1.18 | -6.62 | -4.34 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 14 | 16 | 16 | 19 |
| Avg. Estimate | 55.27M | 43.95M | 159.67M | 207.91M |
| Low Estimate | 13M | 25M | 100M | -- |
| High Estimate | 190M | 170M | 300M | 412M |
| Year Ago Sales | 54.5M | 34.6M | 78.5M | 159.67M |
| Sales Growth (year/est) | 1.40% | 27.00% | 103.40% | 30.20% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -1.65 | -1.58 | -1.27 | -1.42 |
| EPS Actual | -1.25 | -1.18 | -2.53 | -0.97 |
| Difference | 0.4 | 0.4 | -1.26 | 0.45 |
| Surprise % | 24.20% | 25.30% | -99.20% | 31.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.86 | -1.07 | -4.34 | -4.58 |
| 7 Days Ago | -0.86 | -1.07 | -4.34 | -4.58 |
| 30 Days Ago | -1.16 | -1.32 | -5 | -4.81 |
| 60 Days Ago | -1.49 | -1.53 | -5.8 | -6.04 |
| 90 Days Ago | -1.44 | -1.48 | -5.77 | -6.04 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 5 | 4 | 5 | 3 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ARVN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 31.20% | -- | -- | 8.30% |
| Next Qtr. | 9.30% | -- | -- | 10.70% |
| Current Year | 34.40% | -- | -- | 4.90% |
| Next Year | -5.50% | -- | -- | 12.50% |
| Next 5 Years (per annum) | -28.20% | -- | -- | 11.23% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/17/2024 |
| Maintains | Wells Fargo: Overweight to Overweight | 5/9/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 5/8/2024 |
| Maintains | Stifel: Buy to Buy | 5/8/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/8/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 4/15/2024 |
Related Tickers
KYMR Kymera Therapeutics, Inc.
32.96
+0.27%
IMCR Immunocore Holdings plc
41.68
-2.37%
BCYC Bicycle Therapeutics plc
23.04
-0.35%
ETNB 89bio, Inc.
8.10
+0.06%
CYTK Cytokinetics, Incorporated
52.79
+0.98%
OLMA Olema Pharmaceuticals, Inc.
13.13
-1.20%
ALXO ALX Oncology Holdings Inc.
9.01
-2.91%
SWTX SpringWorks Therapeutics, Inc.
40.22
+1.28%
MRUS Merus N.V.
52.90
-1.51%
REPL Replimune Group, Inc.
7.90
+11.11%